These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29989668)

  • 1. Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia.
    Collins M
    J Bone Miner Res; 2018 Aug; 33(8):1381-1382. PubMed ID: 29989668
    [No Abstract]   [Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
    Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
    N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-fibroblast growth factor 23 antibody therapy.
    Fukumoto S
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burosumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is FGF23 the long sought after phosphaturic factor phosphatonin?
    Silve C; Beck L
    Nephrol Dial Transplant; 2002 Jun; 17(6):958-61. PubMed ID: 12032180
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bone and calcium metabolism associated with malignancy. Tumor-induced osteomalacia.].
    Fukumoto S
    Clin Calcium; 2018; 28(11):1451-1455. PubMed ID: 30374000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic diseases resulting from disordered FGF23/klotho biology.
    Econs MJ
    Bone; 2017 Jul; 100():56-61. PubMed ID: 27746322
    [No Abstract]   [Full Text] [Related]  

  • 11. [Inhitibion of FGF23 activities as a possible new treatment for patients with FGF23-related hypophosphatemic diseases].
    Kinoshita Y
    Clin Calcium; 2016 Feb; 26(2):233-9. PubMed ID: 26813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
    Du E; Xiao L; Hurley MM
    J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Iron-Deficiency Anemia and Hypophosphatemia.
    Kommalapati A; Singhi R; Tella SH
    Am J Med; 2018 Mar; 131(3):e103-e104. PubMed ID: 29031590
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
    Fukumoto S
    Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis.
    Rendina D; Esposito T; Mossetti G; De Filippo G; Gianfrancesco F; Perfetti A; Magliocca S; Formisano P; Prié D; Strazzullo P
    J Clin Endocrinol Metab; 2012 May; 97(5):E840-4. PubMed ID: 22419710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia.
    Kinoshita Y; Hori M; Taguchi M; Fukumoto S
    Bone; 2014 Oct; 67():145-51. PubMed ID: 25026495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF23 blockade coming to clinical practice.
    Emma F; Haffner D
    Kidney Int; 2018 Nov; 94(5):846-848. PubMed ID: 30348298
    [No Abstract]   [Full Text] [Related]  

  • 18. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
    Avitan-Hersh E; Tatur S; Indelman M; Gepstein V; Shreter R; Hershkovitz D; Brick R; Bergman R; Tiosano D
    J Clin Endocrinol Metab; 2014 Jan; 99(1):E132-6. PubMed ID: 24243633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice.
    Tomoe Y; Segawa H; Shiozawa K; Kaneko I; Tominaga R; Hanabusa E; Aranami F; Furutani J; Kuwahara S; Tatsumi S; Matsumoto M; Ito M; Miyamoto K
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1341-50. PubMed ID: 20357029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.
    Domrongkitchaiporn S; Disthabanchong S; Cheawchanthanakij R; Niticharoenpong K; Stitchantrakul W; Charoenphandhu N; Krishnamra N
    Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):105-12. PubMed ID: 19449283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.